1. Current standards of neuropsychological assessment in epilepsy surgery centers across Europe;Vogt;Epilepsia,2017
2. Pharmacoresistance – Epidemiology, mechanisms, and impact on epilepsy treatment;Janmohamed;Neuropharmacology,2020
3. Severina, A. I., Kavraiskyi, D. P., Shtrygol, S. Yu., Georgiyants, V. А. (2018). Pat. No. 103378 UA. 5-R-1-Aryl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one with anticonvulsant activity. MPK: A61K 31/50. No. u 2015 06663. declared: 06.07.2015; published: 26.02.2018, No. 4. Available at: http://uapatents.com/7-103378-5-r-1-aril-15-digidro-4n-pirazolo34-dpirimidin-4-oniv-shho-viyavlyayut-protisudomnu-aktivnist.html
4. Screening study of novel pyrazolo[3,4-d]pyrimidine-4-one derivatives for anticonvulsant activity;Kavraiskyi;Pharmacology and drug toxicology,2016
5. Experimental study of new pyrazolo[3,4-D]pyrimidine-4-one derivatives for anticonvulsant activity spectrum;Kavraiskyi;ScienceRise: Pharmaceutical Science,2016-07-01